Back to the overview page

Anneke (AS) de Vos PhD

Department
Blood-borne infections
E-mail
a.devos@sanquin.nl
LinkedIn
https://nl.linkedin.com/in/anneke-vos-de-25356280
Training

Epidemiology (master), Utrecht University - 2013
Biology (bachelor & master), University of Amsterdam - 2008

Thesis

2014
Heterogeneity in risk-behaviour matters; Modelling the spread of HIV and Hepatitis C Virus among Injecting Drug Users.
University of Utrecht

Research interests
  • Mathematical models for the spread of infectious disease
  • Epidemiology
  • Longitudinal data analysis
Technology

R, Mathematica

Resume
2015-present Post-doc at the Dept of Blood-borne Infections, Sanquin, Amsterdam on the project 'How Safe Should Donor Blood Be?'
2009-2014 PhD student at University Medical Center Utrecht, Utrecht
2004-2006 Student-assistent at the University of Amsterdam, Amsterdam (for the bachelor courses in statistics and mathematical modelling)
Publications
Sanquin publications
Other publications

de Vos AS, Prins M, Kretzschmar ME. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction 2015; 110(6):975-83.

de Vos AS, Kretzschmar ME. Benefits of hepatitis C virus treatment: a balance of preventing onward transmission and re-infection. Math Biosci 2014; 258:11-8.

van Santen DK, van der Helm JJ, Grady BP, de Vos AS, Kretzschmar ME, Stolte IG, Prins M. Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status. AIDS 2014; 28(17):2589-99.

de Vos AS, Prins M, Coutinho RA, van der Helm JJ, Kretzschmar ME. Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study. AIDS 2014; 28(6):911-8.

de Vos AS, Kretzschmar ME. The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users. J Theor Biol 2013; 333:126-34.

de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction 2013; 108(6);1070-81.

de Vos AS, van der Helm JJ, Prins M, Kretzschmar ME. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics 2012; 4(2):57-67.

Althaus CL, de Vos AS, De Boer RJ. Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive number, R0. J Virol 2009; 83(15):7659-67.

Claessen D, de Vos AS, de Roos AM. Bioenergetics, overcompensation and the source/sink status of marine reserve. Can J Fish Aquat Sci 2009; 66:1057-71.

Last edited on: 18 December 2015
Back to the overview page